Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Open-Label, Active-Controlled, Multi-Center, Phase III Clinical Study of Anti-PD-1 Antibody SHR-1210 vs. Investigator's Choice of Chemotherapy in Subjects With Locally Advanced or Metastatic Esophageal Cancer

Next Previous
Trial Profile

A Randomized, Open-Label, Active-Controlled, Multi-Center, Phase III Clinical Study of Anti-PD-1 Antibody SHR-1210 vs. Investigator's Choice of Chemotherapy in Subjects With Locally Advanced or Metastatic Esophageal Cancer

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 24 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Camrelizumab (Primary) ; Docetaxel; Irinotecan
  • Indications Carcinoma; Oesophageal cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Acronyms ESCORT
  • Sponsors Jiangsu Hengrui Medicine Co.

    • Most Recent Events

    • 01 Dec 2021 Results assessing PD-L1 Expression on circulating tumor cells for predicting clinical outcomes by using data from six clinical trials including this study published in the Oncologist
    • 15 Nov 2021 Results (N=1683) of meta-analysis and systematic review evaluating the efficacy and safety of PD-1 inhibitors monotherapy versus chemotherapy in second-line treatment of AEC published in the Clinical Therapeutics
    • 13 May 2020 Primary endpoint (Overall Survival (OS)) has been met, as per Results published in the Lancet Oncology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top